Marbofloxacin CAS No. 115550-35-1

Product Description

Marbofloxacin is a third-generation fluoroquinolone antibiotic widely used in veterinary medicine for treating a variety of bacterial infections in dogs and cats. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication and transcription, thereby preventing bacterial growth and causing cell death. This broad-spectrum antibiotic is effective against both Gram-negative and some Gram-positive bacteria, including common pathogens like Pasteurella, Staphylococcus, Escherichia coli, and Pseudomonas. Available in tablet and injectable forms, marbofloxacin is typically administered once daily at a dosage of 2–4 mg/kg, depending on the infection. It is well-absorbed orally with a bioavailability of over 90% in dogs and has a half-life of approximately 12–14 hours, facilitating convenient once-daily dosing. However, it should be used with caution due to potential side effects such as vomiting, diarrhea, and lethargy, and more serious risks like cartilage damage in young animals and central nervous system disorders. It is contraindicated in growing animals and those with existing CNS issues. Marbofloxacin should not be given with calcium, iron, or aluminum-containing products, as these can interfere with its absorption. While it is licensed for veterinary use in many countries, it is not approved for human use.

Send Us a inquiry!

Product Use & Characteristics

Chemical Information:

• Molecular Formula: C17H19FN4O4

• Molecular Weight: 362.4 g/mol

• IUPAC Name: 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid

• Class: Third-generation fluoroquinolone antibiotic

Pharmacological Properties:

• Mechanism of Action: Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.

• Spectrum: Broad-spectrum activity against Gram-negative and some Gram-positive bacteria, including Pasteurella, Staphylococcus, Escherichia coli, and Pseudomonas.

• Pharmacokinetics:

  • Absorption: Well-absorbed orally (bioavailability >90% in dogs).

  • Half-life: ~12–14 hours in dogs, allowing once-daily dosing.

  • Excretion: Primarily renal (unchanged drug and metabolites).

Safety and Side Effects:

• Adverse Effects: Vomiting, diarrhea, lethargy, and, rarely, cartilage damage in young animals.

• Contraindications: Not recommended for growing animals (due to cartilage effects) or animals with CNS disorders (risk of seizures).

Uses

Veterinary Use:

• Approved Species: Dogs and cats (commonly used for respiratory, urinary, and skin infections).

• Formulations: Available as tablets or injectable solutions.

• Dosage: Typically 2–4 mg/kg once daily, depending on the infection.

• Specific Uses:

  • Respiratory infections

  • Urinary tract infections

  • Skin and soft tissue infections

  • Intestinal infections in weaned piglets caused by E. coli

Other Uses:

• Combination Formulations: Marbofloxacin combined with clotrimazole and dexamethasone is available under the name Aurizon.

• Environmental Monitoring: Detection and quantification in veterinary tablets and livestock effluent using electrochemical sensing platforms.

Detection and Analysis

Analytical Methods:

• High-Performance Liquid Chromatography (HPLC): A sensitive and accurate method for simultaneous estimation of Marbofloxacin, Ofloxacin, and Ciprofloxacin in pharmaceutical dosage forms or individually.

  • Column: Hypersil (C18, 150 mm × 4.6 mm, 5 μm particle size)

  • Mobile Phase: Mixture of triethanolamine (1%), acetonitrile (80%), and water

  • Flow Rate: 1.2 mL/min

  • Detector Wavelength: 280 nm

  • Retention Times: Marbofloxacin (4.688 min), Ofloxacin (2.480 min), Ciprofloxacin (1.854 min)

  • Linearity Range: 25–80 µg/mL

  • Validation: Method validated according to ICH Q2(R1) guidelines.

Electrochemical Sensing:

• Platform: ZrMo2O8/MWCNT-COOH composites for the detection of Marbofloxacin.

  • Synergistic Interactions: Between ZrMo2O8 nanoparticles and MWCNT-COOH.

  • Catalytic Activity: Superior catalytic activity toward Marbofloxacin oxidation.

  • Linear Range: 0.01–10 μM

  • Sensitivity: 7.640 μA μM−1

  • Detection Limit: 0.002 μM

  • Anti-Interfering Ability: Strong resistance to potential interfering substances.

  • Storage Stability: Stable response peak current for at least 15 days.

  • Applications: Sensitive determination of Marbofloxacin in veterinary tablets and livestock effluent.

Regulatory Status

• Approval: Licensed for veterinary use in many countries, including the European Union, the USA, and Canada.

• Clinical Trials: Maximum clinical trial phase of II.

Environmental Impact

• Persistence: Residues persist in the environment, causing adverse effects on human health and ecosystems.

• Health Risks: Improper usage can lead to increased bacterial resistance, immune function deterioration, and environmental contamination.

• Detection: Development of sensitive techniques for detecting trace amounts of Marbofloxacin residues in various matrices is crucial for environmental monitoring and safety.

Why us!

Qingdao Sigma Chemical Co., Ltd., established in January 2017 and headquartered in Qingdao, China, is a reliable chemical supplier. Specializing in pharmaceuticals, biochemical intermediates, and research chemicals, the company offers a diverse product portfolio, including peptides (e.g., Tirzepatide, Semaglutide), nootropics, veterinary products, and APIs, often marketed with ≥99% purity and COA certification. We provides R&D, custom synthesis, and contract manufacturing services at various scales, while claiming a global export presence across 100+ countries. With international warehouses in the USA, Europe, Australia, and Canada, Qingdao Sigma Chemical also facilitates drop-shipping and reshipments, positioning itself as a key supplier for laboratory and research applications.